ALMEIDA TORO, JUAN MANUEL
Preferred name
ALMEIDA TORO, JUAN MANUEL
Main Affiliation
Email
jalmeida@udd.cl
Scopus Author ID
57202465700
12 results
Now showing 1 - 10 of 12
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 2 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Topic: AS15 COVID and Stroke IMPACTOF COVID-19 PANDEMIC ON STROKE SEVERITYAND MORTALITY IN THE SOUTH-EAST OF SANTIAGO, CHILE(2021); ; ;GARCÍA PRADO, DIEGO RICARDO ;Silva, A.Vallejos, J.5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience(2020); ; ;Gabriel Cavada ;Eloy MansillaAlexis Rojo<jats:p>Abstract Background: Low-dose alteplase (LrtPA) has been shown not to be inferior to the standard-dose (SrtPA) with respect to death/disability. Objective: We aim to evaluate the percentage of patients treated with LrtPA at our center after the ENCHANTED trial and the factors associated with the use of this dosage. Methods: Prospective study in consecutive patients with an acute stroke admitted between June 2016 and November 2018. Results: 160 patients were treated with intravenous thrombolysis, 50% female; mean age 65.4±18.5 years. Of these, 48 patients (30%) received LrtPA. In univariate analysis, LrtPA was associated with patient's age (p=0.000), previous modified Rankin scale scores (mRS) (p<0.000), hypertension (p=0.076), diabetes mellitus (p=0.021), hypercholesterolemia (p=0.19), smoking (p=0.06), atrial fibrillation (p=0.10), history of coronary artery disease (p=0.06), previous treatment with antiplatelet agents (p<0.000), admission International Normalized Ratio-INR (p=0.18), platelet count (p=0.045), leukoaraiosis on neuroimaging (p<0.003), contraindications for thrombolytic treatment (p=0.000) and endovascular treatment (p=0.027). Previous relevant bleedings were determinants for treatment with LrtPA. Final diagnosis on discharge of stroke mimic was significant (p=0.02) for treatment with SrtPA. In multivariate analysis, mRS (OR: 2.21; 95%CI 1.37‒14.19), previous antiplatelet therapy (OR: 11.41; 95%CI 3.98‒32.70), contraindications for thrombolysis (OR: 56.10; 95%CI 8.81‒357.80), leukoaraiosis (OR: 4.41; 95%CI 1.37‒14.10) and diagnosis of SM (OR: 0.22; 95%CI 0.10‒0.40) remained independently associated. Conclusions: Following the ENCHANTED trial, LrtPA was restricted to 30% of our patients. The criteria that clinicians apply are based mostly on clinical variables that may increase the risk of brain or systemic hemorrhage or exclude the patient from treatment with lytic drugs.</jats:p>Scopus© Citations 2 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Global Impact of COVID-19 on Stroke Care and IV Thrombolysis(2021) ;Raul G. Nogueira ;Muhammad M. Qureshi ;Mohamad Abdalkader ;Sheila Ouriques MartinsHiroshi YamagamiScopus© Citations 87 9 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial(Elsevier BV, 2025-05) ;Craig S Anderson ;Debbie Summers ;Menglu Ouyang ;Yi SuiBrenda Johnson2Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Stroke awareness and response in Chile: a transversal study using a telephone survey(2021) ;Mazzon, E ;Navia, V. ;Hoffmeister, L.; 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 7Scopus© Citations 19 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Stroke care and collaborative academic research in Latin America(2022); ; ;Francisca Urrutia; <jats:p>Objective. A narrative overview of regional academic research collaborations to address the increasing burden and gaps in care for patients at risk of, and who suffer from, stroke in Latin America (LA). Materials and methods. A summary of experiences and knowledge of the local situation is presented. No systematic literature review was performed. Results. The rapidly increasing burden of stroke poses immense challenges in LA, where prevention and management strategies are highly uneven and inadequate. Clinical research is increasing through various academic consortia and networks formed to overcome structural, funding and skill barriers. However, strengthening the ability to generate, analyze and interpret randomized evidence is central to further develop effective therapies and healthcare systems in LA. Conclusions. Regional networks foster the conduct of multicenter studies –particularly randomized controlled trials–, even in resource-poor regions. They also contribute to the external validity of international studies and strengthen systems of care, clinical skills, critical thinking, and international knowledge exchange.</jats:p>10 1Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Incidence, risk factors, prognosis, and health-related quality of life after stroke in a low-resource community in Chile (ÑANDU): a prospective population-based study(2021); ; ;Ana M Moraga ;Angelica VejarCarolina VidalScopus© Citations 72 14